期刊
SAUDI JOURNAL OF OPHTHALMOLOGY
卷 28, 期 1, 页码 19-30出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.sjopt.2013.12.003
关键词
Dry eye; Anti-inflammatory; Keratoconjunctivitis sicca; Keratitis sicca; Xerophthalmia; Mucin secretion; Tear secretion; NSAID
资金
- Spanish Ministry of Economy and Competition (MICINN) [SAF2010-16024]
- Ministry of Health Social Services and Equality RETICS [RD12/0034/0003]
Dry eye syndrome is a common tears and ocular surface multifactorial disease, described by changes in the ocular surface epithelia related to reduced tears quantity and ocular surface sensitivity, leading to inflammatory reaction. Managing the eye inflammation proved helpful to patients with dry eye disease and current treatment is based on the use of topically applied artificial tear products/lubricants, tear retention management, stimulation of tear secretion and using anti- inflammatory drugs. In this article we revise the corresponding literature and patents assembling the new treatment approaches of novel and future pharmaceutical compounds destined for the dry eye disease treatment. The most frequent categories of compounds presented are secretagogues and anti- inflammatory drugs. These compounds are the research outcome of novel therapeutic strategies designed to reduce key inflammatory pathways and restore healthy tear film.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据